WHO activities in the European region
Transcript of WHO activities in the European region
![Page 1: WHO activities in the European region](https://reader035.fdocuments.net/reader035/viewer/2022062322/62aa40e3bcb2567778339d04/html5/thumbnails/1.jpg)
WHO activities in the European region
Hanne Bak Pedersen
Programme Manager, Health Technologies and Pharmaceuticals
Division of Health Systems and Public Health
PPRI Summer School , Vienna, August 2017
![Page 2: WHO activities in the European region](https://reader035.fdocuments.net/reader035/viewer/2022062322/62aa40e3bcb2567778339d04/html5/thumbnails/2.jpg)
Presentation outline
• WHO’s role and responsibilities
• Key health indicators, European Region
• Main challenges in access to medicines in the WHO European Region
• SDGs and access to medicines related action to address challenges
![Page 3: WHO activities in the European region](https://reader035.fdocuments.net/reader035/viewer/2022062322/62aa40e3bcb2567778339d04/html5/thumbnails/3.jpg)
WHO
• The UN specialized agency for health
• 194 Member States
• 800+ Collaborating Centers
• Approximately 7 000 public health experts including
doctors, pharmacists, nurses, epidemiologists, scientists,
managers, administrators
• 147 country offices, 6 regional offices, 1 headquarters
![Page 4: WHO activities in the European region](https://reader035.fdocuments.net/reader035/viewer/2022062322/62aa40e3bcb2567778339d04/html5/thumbnails/4.jpg)
WHO
![Page 5: WHO activities in the European region](https://reader035.fdocuments.net/reader035/viewer/2022062322/62aa40e3bcb2567778339d04/html5/thumbnails/5.jpg)
WHO European Region
• 53 Member States
• 900 million inhabitants
• 4 official languages
• Regional office in Copenhagen
• 29 country offices
• 5 geographically dispersed offices
![Page 6: WHO activities in the European region](https://reader035.fdocuments.net/reader035/viewer/2022062322/62aa40e3bcb2567778339d04/html5/thumbnails/6.jpg)
Life expectancy at birth
![Page 7: WHO activities in the European region](https://reader035.fdocuments.net/reader035/viewer/2022062322/62aa40e3bcb2567778339d04/html5/thumbnails/7.jpg)
Premature mortality
![Page 8: WHO activities in the European region](https://reader035.fdocuments.net/reader035/viewer/2022062322/62aa40e3bcb2567778339d04/html5/thumbnails/8.jpg)
Total expenditure on health as a
proportion of GDP
![Page 9: WHO activities in the European region](https://reader035.fdocuments.net/reader035/viewer/2022062322/62aa40e3bcb2567778339d04/html5/thumbnails/9.jpg)
Out of pocket expenditure
![Page 10: WHO activities in the European region](https://reader035.fdocuments.net/reader035/viewer/2022062322/62aa40e3bcb2567778339d04/html5/thumbnails/10.jpg)
Main challenges in access to medicines in the WHO
European Region
• Quality: weak regulatory practices in some countries give room to circulation of falsified or poor quality medicines. Uncontrolled internet selling is of concern, etc.
• Prices: new high-price medicines creates issues on future sustainability of the health systems and UHC. High out-of-pocket payments for medicines in some countries.
• Procurement / shortages: vital out of patent medicines are not interesting to manufacturers anymore due to production and/or profit related matters. Low capability to forecast demand in some settings.
• Responsible use: lack of national consolidated prescribing policies/ guidance on use as well as over the counter selling of prescription only medicines
![Page 11: WHO activities in the European region](https://reader035.fdocuments.net/reader035/viewer/2022062322/62aa40e3bcb2567778339d04/html5/thumbnails/11.jpg)
Sustainable Development Goals
![Page 12: WHO activities in the European region](https://reader035.fdocuments.net/reader035/viewer/2022062322/62aa40e3bcb2567778339d04/html5/thumbnails/12.jpg)
20162007 2008 2012 20151978 1996
Glo
bal
co
mm
itm
ents
WHA 28.66
WHA60.16
WHA 69.25
SDGs
1975 1977 19941988 2013 2014
First model list
of essential
drugs
Alma-Ata
Declaration
WHA 41.16
WHA47.13
WHA 67.20,
67.21, 67.22WHA61.21
EB132.R4
Access to medicines and technologies
WHA 67.25, 68.7
![Page 13: WHO activities in the European region](https://reader035.fdocuments.net/reader035/viewer/2022062322/62aa40e3bcb2567778339d04/html5/thumbnails/13.jpg)
Access framework
1- Assured quality2- Affordable prices and
sustainable financing
4- Responsible selectionand use
3-Reliable and efficient supply chain
Good governance
![Page 14: WHO activities in the European region](https://reader035.fdocuments.net/reader035/viewer/2022062322/62aa40e3bcb2567778339d04/html5/thumbnails/14.jpg)
Working towards country cooperation to improve
access to medicines in Europe
2014 2015 2016 2017 2018+
Prospective country collaboration on technical capacity for strategic procurement
![Page 15: WHO activities in the European region](https://reader035.fdocuments.net/reader035/viewer/2022062322/62aa40e3bcb2567778339d04/html5/thumbnails/15.jpg)
WHO EURO support to Member States
• Networks of national authorities in the Region on
– Pricing and reimbursement policies in collaboration with the WHO CC PPRI (Austrian Public Health Institute)
– Medical product regulation
– Strategic procurement
– Responsible use of medicines incl drug utilization monitoring and analysis with a specific focus on use of antimicrobials – through the AMC network
• Support national capacity development for example
– for efficiency in regulation and use of medicines; - benchmarking of NRAs and training of medicines assessors;
– policy development for sustainable access to medicines;
• Overall awareness and knowledge sharing in the medical product are for example through data analysis and publications
![Page 16: WHO activities in the European region](https://reader035.fdocuments.net/reader035/viewer/2022062322/62aa40e3bcb2567778339d04/html5/thumbnails/16.jpg)
Thank you